Undisclosed strategic investor

← Back to your selection

Activity in this selectionbalderton-a1d7b951

Rounds participated in: 1
Confirmed lead rounds: —
New companies: 1
Funding in participating rounds: $55M

By stage

Series C+1

By primary sector

Healthtech1

By country

United States1

Rounds

1 in this selection

Sep 2

Elucid

Clinically validated medical-imaging software that analyzes CT angiography to characterize arterial plaque and help clinicians assess cardiovascular risk.

$55MSeries D

Role not disclosed